Search

Author/Creator Dalal, Darshan

1. Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. (12th July 2017)

Authors:
Hughes, Timothy P.; Munhoz, Eduardo; Aurelio Salvino, Marco; Ong, Tee Chuan; Elhaddad, Alaa; Shortt, Jake; Quach, Hang; Pavlovsky, Carolina; Louw, Vernon J.; Shih, Lee‐Yung; Turkina, Anna G.; Meillon, Luis; Jin, Yu; Acharya, Sandip; Dalal, Darshan; Lipton, Jeffrey H.
Journal:
British journal of haematology
Issue:
Volume 179:Number 2(2017)
Page Start:
219
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Prospective Observational Study of Implantable Cardioverter‐Defibrillators in Primary Prevention of Sudden Cardiac Death: Study Design and Cohort Description. Issue 1 (22nd February 2013)

Authors:
Cheng, Alan; Dalal, Darshan; Butcher, Barbara; Norgard, Sanaz; Zhang, Yiyi; Dickfeld, Timm; Eldadah, Zayd A.; Ellenbogen, Kenneth A.; Guallar, Eliseo; Tomaselli, Gordon F.
Journal:
Journal of the American Heart Association
Issue:
Volume 2:Issue 1(2013:Feb.)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. Issue 1 (2nd January 2020)

Authors:
Cortes, Jorge; Huynh, Lynn; Mendelson, Estella; Brandt, Patricia; Dalal, Darshan; DerSarkissian, Maral; Cortina, Diego; Narkhede, Sahil; Sheng Duh, Mei
Journal:
Leukemia & lymphoma
Issue:
Volume 61:Issue 1(2020)
Page Start:
98
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗